Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Zhujiang Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06449833CT.gov Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | — | Recruiting | — | — | — |
NCT05313529CT.gov LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes | — | Active Not Recruiting | — | — | — |
NCT04371978CT.gov Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 | — | Terminated | — | — | — |
NCT02372630CT.gov The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Linagliptin (this asset) | Zhujiang Hospital | Approved | B · 58 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Testosterone Undecylate | Alexandra Kautzky-Willer | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Linagliptin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | B · 56 |
| Glucose Metabolism Disease | — | P3 | CCC · 54 |
| COVID-19 | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Linagliptin in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/linagliptin-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →